Could Acadia Pharmaceuticals (ACAD) Be 30% Undervalued Following Mixed Q3 Results?
Acadia Pharmaceuticals (ACAD) has released its third quarter 2026 results, reporting revenue of US$342.29 million and net income of US$53.52 million. The announcement has drawn renewed attention to the stock.
The Q3 2026 report slots into a mixed year for Acadia Pharmaceuticals. The 1 day share price return of 4.38% and 30 day share price return of 8.76% partially offset a 90 day share price decline of 26.50%. Over a longer horizon, total shareholder return is down 0.83% over 1 year and 2.45% over 3 years, with a 5 year total shareholder return of 3.82%. This suggests recent momentum has weakened even as the latest earnings have refocused attention on both growth prospects and perceived risk.
Scan how Acadia Pharmaceuticals compares with other biopharma stocks showing mixed earnings momentum and sharpen your watchlist using the hand picked 19 high quality undiscovered gems.
For Acadia Pharmaceuticals, a jump after mixed earnings can mean two very different things. Is this move catching up to the underlying business, or just a short term swing in sentiment before valuation bites again?
Most Popular Narrative: 30% Undervalued
Against the last close at $21.47, the most followed narrative for Acadia Pharmaceuticals points to a fair value of $30.53. This frames the recent share price weakness as a gap between what the market pays today and what modeled cash flows suggest.
Disciplined capital allocation through reduced 2026 R&D guidance to US$355 million to US$380 million, while maintaining a cash balance of US$956 million and continuing to invest in a pipeline that management estimates could support about US$11b in global peak sales potential, points to a framework where earnings and cash flow could rise if new products are approved and launched on top of the existing DAYBUE and NUPLAZID base.
See why 56 investors see Acadia Pharmaceuticals as 30% undervalued.
Result: Fair Value of $30.53 (UNDERVALUED)
Still, the narrative around Acadia Pharmaceuticals can change quickly if remlifanserin setbacks deepen or if DAYBUE and NUPLAZID fall short of revenue expectations.
Find out about the key risks to this Acadia Pharmaceuticals narrative.
Next Steps
Mixed signals around Acadia Pharmaceuticals do not have to leave you on the fence. Move quickly, look through both sides of the story, and weigh the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Acadia Pharmaceuticals?
If you stop with Acadia Pharmaceuticals, you see only one corner of the market. Cast a wider net so you do not miss what fits you better.
- Target potential mispricing opportunities by scanning the 34 high quality undervalued stocks that combine solid business quality with prices the market might be discounting.
- Prioritise resilience and sleep better at night by focusing on the 31 resilient stocks with low risk scores that score well on financial strength and risk metrics.
- Zero in on financially robust operators through the list of solid balance sheet and fundamentals (25 results) and build a shortlist that can better handle stress without constant surprises.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com